ArticleEye (London, England)2025

FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings - FORCE study.

Ashish Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.